120 related articles for article (PubMed ID: 30396964)
1. Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S
Anticancer Res; 2018 Nov; 38(11):6399-6404. PubMed ID: 30396964
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
Tumour Biol; 2007; 28(4):212-20. PubMed ID: 17717427
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.
Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S
Anticancer Res; 2019 Apr; 39(4):1953-1957. PubMed ID: 30952738
[TBL] [Abstract][Full Text] [Related]
5. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
[TBL] [Abstract][Full Text] [Related]
7. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
9. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer.
Bendardaf R; Lamlum H; Ristamäki R; Syrjänen K; Pyrhönen S
Oncol Rep; 2008 Nov; 20(5):999-1004. PubMed ID: 18949393
[TBL] [Abstract][Full Text] [Related]
10. Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
Yuuki S; Komatsu Y; Fuse N; Kato T; Miyagishima T; Kudo M; Watanabe M; Tateyama M; Kunieda Y; Wakahama O; Sakata Y; Asaka M
Clin Drug Investig; 2010; 30(4):243-9. PubMed ID: 20225907
[TBL] [Abstract][Full Text] [Related]
11. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
[TBL] [Abstract][Full Text] [Related]
12. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
13. Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression.
Scartozzi M; Bianchi F; Rosati S; Galizia E; Antolini A; Loretelli C; Piga A; Bearzi I; Cellerino R; Porfiri E
J Clin Oncol; 2002 Mar; 20(5):1203-8. PubMed ID: 11870161
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F
Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894
[TBL] [Abstract][Full Text] [Related]
15. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
[TBL] [Abstract][Full Text] [Related]
16. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
17. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy.
Brueckl WM; Moesch C; Brabletz T; Koebnick C; Riedel C; Jung A; Merkel S; Schaber S; Boxberger F; Kirchner T; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2003; 23(2C):1773-7. PubMed ID: 12820457
[TBL] [Abstract][Full Text] [Related]
18. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast.
Son BH; Ahn SH; Ko CD; Ka IW; Gong GY; Kim JC
Breast J; 2004; 10(1):20-6. PubMed ID: 14717755
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Berlin J; Posey J; Tchekmedyian S; Hu E; Chan D; Malik I; Yang L; Amado RG; Hecht JR
Clin Colorectal Cancer; 2007 Mar; 6(6):427-32. PubMed ID: 17531105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
